Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of ProALL microRNAs in Blood Specimen for Prediction of Acute Lymphoblastic Leukemia Relapse Risk

NCT03000335 is registered in ClinicalTrials.gov with Curewize Health Ltd. as lead sponsor.

NCT NCT03000335
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03000335 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of ProALL microRNAs in Blood Specimen for Prediction of Acute Lymphoblastic Leukemia Relapse Risk
Lead sponsor
Curewize Health Ltd.
Phase
Observational
Overall status
Unknown status
Start date
December 31, 2016
Completion date
December 31, 2021
Enrollment
65 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell acute lymphoblastic leukemia